全文获取类型
收费全文 | 2578篇 |
免费 | 215篇 |
国内免费 | 4篇 |
专业分类
2797篇 |
出版年
2021年 | 31篇 |
2020年 | 17篇 |
2019年 | 35篇 |
2018年 | 28篇 |
2017年 | 21篇 |
2016年 | 50篇 |
2015年 | 65篇 |
2014年 | 106篇 |
2013年 | 105篇 |
2012年 | 160篇 |
2011年 | 161篇 |
2010年 | 103篇 |
2009年 | 99篇 |
2008年 | 138篇 |
2007年 | 140篇 |
2006年 | 141篇 |
2005年 | 137篇 |
2004年 | 156篇 |
2003年 | 124篇 |
2002年 | 150篇 |
2001年 | 25篇 |
2000年 | 16篇 |
1999年 | 32篇 |
1998年 | 28篇 |
1997年 | 31篇 |
1996年 | 29篇 |
1995年 | 26篇 |
1994年 | 22篇 |
1993年 | 29篇 |
1992年 | 29篇 |
1991年 | 25篇 |
1990年 | 17篇 |
1989年 | 21篇 |
1988年 | 19篇 |
1987年 | 20篇 |
1986年 | 20篇 |
1985年 | 16篇 |
1984年 | 29篇 |
1983年 | 24篇 |
1982年 | 31篇 |
1981年 | 47篇 |
1980年 | 27篇 |
1979年 | 24篇 |
1978年 | 25篇 |
1977年 | 23篇 |
1976年 | 25篇 |
1975年 | 26篇 |
1974年 | 21篇 |
1973年 | 20篇 |
1971年 | 14篇 |
排序方式: 共有2797条查询结果,搜索用时 0 毫秒
1.
Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These “cancer stem cells” are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses. 相似文献
2.
3.
4.
Vinyl chloride (VC) is used as an example to demonstrate how biological information can be incorporated into quantitative risk assessment. The information included is the pharmacokinetics of VC in animals and humans and the data-generated hypothesis that VC primarily affects the initiation stage of the multistage carcinogenesis. The emphasis in this paper is on the improvement of risk assessment methodology rather than the risk assessment of VC per se.Sufficient data are available to construct physiologically-based pharmacokinetic models for both animals and humans. These models are used to calculate the metabolized dose corresponding to exposure scenarios in animals and in humans.On the basis of the data on liver angiosarcomas and carcinomas in rats, the cancer risk per unit of metabolized dose is comparable, irrespective of routes (oral or inhalation) of exposure. The tumor response from an intermittent/partial lifetime exposure is shown to be consistent with that from a lifetime exposure when VC is assumed to affect the first (initiation) stage of the multistage carcinogenic process. Furthermore, the risk estimates calculated on the basis of animal data are shown to be consistent with the human experience. 相似文献
5.
Jerry W. McClure 《Phytochemistry》1974,13(7):1065-1069
Five-day-old etiolated barley shoots respond to brief illumination with red light by increasing their level of PAL ca 50% within 5 hr. When assayed s 相似文献
6.
7.
8.
Extraction of Carnegiea gigantea yielded a new 3,4-dihydroisoquinoline alkaloid, dehydroheliamine; the structure was confirmed by synthesis. 相似文献
9.
The optimal sequence of irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer remains unclear. We conducted a population-based observational study by retrospectively reviewing records from Taiwan’s National Health Insurance Research Database to explore this issue. Patients aged ≥20 years with metastatic colorectal cancer newly diagnosed between 2004 and 2008 (n = 9490) were enrolled in current study. Among these 9490 patients, 3895 patients (41.04%) did not receive any chemotherapy within the first three months after catastrophic illness registration. Patients who received best supportive care were older and had higher Charlson comorbidity indexes and incidences of comorbidities than those who received irinotecan-based regimens, oxaliplatin-based regimens, and 5-fluorouracil/capecitabine alone. Patients who received irinotecan followed by oxaliplatin-based regimens and those who received the reverse sequence were further stratified into arm A (n = 542) and arm B (n = 1156), respectively. The median first time to next treatment was not significantly different between arm A and arm B (210 days vs. 196 days; p = 0.17). However, the median second time to next treatment was longer in arm A than in arm B (155 days vs. 123 days; p = 0.006), which translated into a better overall survival (487 days vs. 454 days; p = 0.02). The crossover rate was higher in arm A than in arm B (47.84% vs. 41.61%; p<0.001). Multivariate Cox regression analyses showed that overall survival was comparable between the two chemotherapy sequences (p = 0.27). Our study suggested that irinotecan followed by oxaliplatin-based regimens might be a better chemotherapy treatment option for metastatic colorectal cancer than the reverse sequence given the higher crossover rate and potential overall survival benefit. 相似文献
10.